Mineralys Therapeutics (MLYS) Makes Progress With FDA For Hypertension

Mineralys Therapeutics Inc. (NASDAQ:MLYS) is one of the 11 Best Day Trading Stocks to Buy Now.

Biopharmaceutical company Mineralys Therapeutics Inc. (NASDAQ:MLYS) scored a win on March 9th when it announced that the Food and Drug Administration (FDA) had accepted its New Drug Application (NDA) for its lorundrostat drug to treat hypertension when combined with other hypertensive drugs. As part of the release, the firm’s CEO outlined that while the drug’s Explore-OSA trial did not show a reduction in the apnea-hypopnea index (AHI), the drug’s safety profile and its impact on blood pressure were nevertheless meaningful.

The FDA’s NDA approval came after Mineralys Therapeutics Inc. (NASDAQ:MLYS) announced in January that it had submitted the application. In December 2025, Bank of America raised the firm’s share price target to $46 from $43 and kept a Buy rating on the stock. The coverage came after Mineralys Therapeutics Inc. (NASDAQ:MLYS)’s earnings report for the third quarter of 2025, which saw the firm confirm that it had a cash runway up to 2027.

Mineralys Therapeutics (MLYS) Makes Progress With FDA For Hypertension

Jirsak / shutterstock.com

Mineralys Therapeutics Inc. (NASDAQ:MLYS) is a biotechnology company that is focused on developing drugs for ailments stemming from aldosterone dysregulation. It is headquartered in Radnor, Pennsylvania.

While we acknowledge the risk and potential of MLYS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MLYS and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None.  Follow Insider Monkey on Google News.